Category: CannabisNewsWire Release

Lexaria Bioscience Corp. (NASDAQ: LEXX) Encouraged by Positive Findings from its DIAB-A22-1 Animal Model Study on Potential DehydraTECH-CBD(TM) Treatment for Diabetes

  • Lexaria’s DIAB-A22-1 animal model study just concluded, highlighting three positive outcomes, including an improvement in general activity, significant reductions in body weight, and improved triglyceride and cholesterol levels
  • The study was undertaken by a third-party testing laboratory in Canada involving 24 obese and eight lean rats for a total of 32 male Zucker rats
  • The success of this DIAB-A22-1 study marks a significant milestone for Lexaria, even as it continues to explore its patented DehydraTECH(TM) technology application in various other areas, including nicotine replacement, epilepsy, hypertension, dementia and more
  • With its unique product offering, a growing list of patents, and unique market positioning, Lexaria is becoming a key player in the drug delivery technology space

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, just announced the completion of its DIAB-A22-1 animal model study, which explored the potential of the patented DehydraTECH(TM)-processed CBD to treat diabetes. Of note were three positive outcomes, including an improvement in general activity, reductions in body weight, and better triglyceride and cholesterol levels.

The study, undertaken by a leading, third-party testing laboratory in Canada, administered select Lexaria “DehydraTECH-CBD 2.0” formulations with doses of either 30 mg/Kg or 100 mg/Kg of body weight. It involved 24 obese and eight lean rats for a total of 32 male Zucker (“ZDF”) rats. As Lexaria’s first study in the diabetes animal model, the company is encouraged by the positive findings. Moreover, it is confident that the results indicate many prospective benefits worthy of further investigation together, possibly with other drugs that help to control glucose levels directly.

Lexaria set out to explore the therapeutic utility of DehydraTECH-CBD against diabetes in November 2022, on the heels of the success of its clinical studies on hypertension. The company’s management was optimistic that the results from the hypertension study would be replicated in the diabetes study, given that hypertension is twice as frequent in people with diabetes, and hypertensive patients are at greater risk of developing diabetes.

The success of this DIAB-A22-1 study marks a significant milestone for Lexaria, even as it continues to explore DehydraTECH’s application in various other areas, including nicotine replacement, epilepsy, hypertension, dementia and more. With DehydraTECH having proven to increase the effectiveness and the way active pharmaceutical ingredients enter the bloodstream, Lexaria is exploring its full potential for improving consumer products. Its efforts have seen the company awarded 28 patents, with more patents pending worldwide.

Diabetes is the 7th largest cause of death in the United States and accounts for an estimated value of $26.7 billion in the global diabetes devices market. Lexaria’s management is hopeful that its current efforts and studies will inch the company closer to taking advantage of this industry’s market potential. In 2021, the global diabetes drug market was estimated at $63.1 billion and is projected to hit $80.65 billion by 2027. With the company’s unique technology, a growing list of patents, and unique market positioning, Lexaria is set to capitalize on this growth and become a leader in the drug delivery technology space.

For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.cannabisnewswire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.cannabisnewswire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is part of the InvestorBrandNetwork.

420 with CNW — Pittcon Research Could Help Regulate Levels of Synthetic and Natural Cannabinoids

Psychedelics and cannabis are probably two of the most common psychoactive drugs, or substances that change physiological and psychological functions. These drugs can affect daily life in both negative and positive ways when used.

For instance, when administered correctly, cannabis may be used as a therapeutic option for a range of neurological conditions such as Alzheimer’s, Parkinson’s and brain cancer. Contrarily, recreational cannabis has been linked to issues with mood, cognition and other symptoms.

Cannabinoids, which are naturally occurring substances in the marijuana plant, are what cause the drug’s psychological and physical side effects. The most popular cannabinoids are tetrahydrocannabinol (THC), cannabidiol (CBD) and cannabigerol (CBG). While THC gives cannabis its “high,” CBD and CBG affect pain perception, appetite and memory and are primarily used to treat diseases such as multiple sclerosis and reduce inflammation and anxiety.

The increased legalization of cannabis has led to the emergence of many products that are now available for both recreational and medical use. But to keep up with the rapidly evolving cannabinoid market, there is now a need to diversify policies in public health.

Developing novel methods for analyzing psychoactive substances using techniques such as liquid chromatography, gas chromatography and mass spectrometry can assist in addressing some of the cannabis therapeutic and regulatory issues.

On the flip side, synthesized cannabinoids are artificial chemicals that mimic the effects of marijuana but are more hazardous as a food additive than natural cannabinoids because they are less well-known, less predictable and have unpredictable effects. Sometimes, producers of marijuana-based products add synthetic cannabinoids to their products because they are easier, quicker and cheaper to produce. Consumers are at risk from this practice, however, as it increases the likelihood of product contamination and lowers quality. Synthetic cannabinoids can also have negative side effects and are difficult to regulate.

The development of innovative drugs will play a significant role in the rapid, efficient and accurate identification and quantification of both natural and synthetic cannabinoids, which will be a major step toward developing regulatory policy and implementing health interventions. As a result, more research on cannabinoids’ effects and biochemistry is required.

Pittcon is at the leading edge of this research, pushing the boundaries of study into psychoactive substances. Researchers are expected to present a number of studies that have examined marijuana and other psychoactive substances at Pittcon this year. The presentations will be crucial to advancing innovation in the cannabis and psychedelics industries, assisting in the better formulation of strategies to curtail the inappropriate use of these substances and develop potential medical treatments.

Industry experts and scientists will highlight the technologies and methodologies used to identify and measure levels of cannabinoids as well as evaluate the quality of cannabinoid products on legal and illegal markets.

As more resources are directed towards understanding both natural and synthetic cannabinoids, innovative products, such as indoor “microgardens” from manufacturers like Advanced Container Technologies Inc. (OTC: ACTX) are also becoming available on the market across the country.

NOTE TO INVESTORS: The latest news and updates relating to Advanced Container Technologies Inc. (OTC: ACTX) are available in the company’s newsroom at https://cnw.fm/ACTX

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

420 with CNW — Missouri Expunges at Least 7,500 Cannabis Convictions

Missouri has expunged the records of more than 7,500 people who had prior cannabis-related convictions. The state legalized recreational cannabis last year after voters approved an amendment to allow adults aged 21 and older to purchase, possess and consume cannabis.

On top of legalizing recreational cannabis, the constitutional amendment also allowed individuals convicted of nonviolent cannabis offenses to petition for release from prison, parole and expungements of their records.

Riverfront Times reports that the measure kicked off a process of expunging cannabis offenses from criminal records. Misdemeanors have made up the majority of the cases that have been expunged so far, the report says, with courts expunging 6,121 nonviolent marijuana-related misdemeanors and more than 1,200 felony convictions.

Misdemeanors that involved driving under the influence of cannabis or selling cannabis to minors did not qualify for the expungement. Individuals who are currently incarcerated for qualified cannabis offenses qualify for the expungement and at least one person has already been released.

The expungement process is going faster than expected, said secretary of the National Organization for the Reform of Marijuana Laws (NORML) Dan Viets. Viets coauthored the state’s recreational and medical cannabis regulations. Overall, it seems like Missouri is fast-tracking its efforts to implement recent cannabis laws.

Adult-use cannabis sales began earlier than expected and just a month after the state Department of Health and Senior Services (DHSS) said that it was nearly done drafting rules for the new recreational cannabis program. The department said in January that once the new rules were effective, it would begin approving requests from licensed medical cannabis dispensaries to convert their licenses and allow them to sell both medical and recreational cannabis.

The DHSS also said that it would begin taking applications to allow people aged 21 years and older to grow cannabis at home for personal use in enclosed and locked facilities.

Amendment 3 set deadlines for courts to complete expungements for people with nonviolent marijuana-related offenses. The deadline for people who are currently serving time for cannabis-related misdemeanors was March 8, 2023, while the deadline for expunging other crimes is around three and a half months away, the Times said. Circuit courts have until June 8, 2023, to facilitate the expungement of all misdemeanor cannabis offenses for individuals who aren’t under the Department of Correction’s supervision.

Furthermore, the state’s circuit courts have up to December 8, 2023, to expunge the records of people who had already served time for federal cannabis offenses that are now considered legal activities.

Meanwhile, significant strides forward are being made by companies such as India Globalization Capital Inc. (NYSE American: IGC), which specialize in developing medicinal formulations from various cannabinoids, such as THC.

NOTE TO INVESTORS: The latest news and updates relating to India Globalization Capital Inc. (NYSE American: IGC) are available in the company’s newsroom at https://cnw.fm/IGC

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

420 with CNW — How Oklahoma’s Marijuana Landscape Could Evolve Once Adult-Use Cannabis is Legalized

There were a lot of concerns when Oklahoma voters approved medical marijuana in 2018. It was unclear how the marijuana industry would develop. The number of marijuana businesses also skyrocketed with very little regulation, making the state the largest holder of licensed marijuana businesses in 2020.

Several years after the voting, those queries are still being raised. State Question 820 was up for vote on March 7, 2023, when voters went to the polls. The measure would legalize marijuana use for adults over the age of 21, allow for the growth of up to six marijuana plants, and open the door to expunging some prior cannabis-related offenses.

Cannabis legalization, according to panelists at an SQ 820 online town hall hosted by the ACLU in January, would enable state businesses to compete with the black market.

There are more than 373,000 medical cannabis users in Oklahoma, according to the Medical Cannabis Authority, the body in charge of the state’s cannabis market. Additionally, there are more than 2,700 dispensaries and over 7,000 growers.

The processing of new grower, dispensary and processor license applications was, however, halted last year by the HB 3208 bill. This bill was approved by the state legislature and signed by Governor Kevin Stitt. This moratorium was in effect starting in August 2022 and could last up to two years.

Legislators have also stated that it is challenging to control the industry since the approval of SQ 788, the measure that legalized medical marijuana in 2018.

Businesses are hopeful and eager to enter new markets if SQ 820 is approved. According to Arshad Lasi, CEO of Nirvana Group, the marijuana industry is prepared to face the complexity of entering the recreational market. However, he claims that some medical cannabis patients are still hesitant because they are concerned about what might happen. They believe that since the market for recreational or adult-use products is a bit larger, prices may go up, quality may decline, or consumers will be given more preferential treatment.

And while some business operators perceive the legalization of recreational marijuana as a threat to local businesses due to invasion by multistate businesses, Lasi believes that adult-use cannabis increases market share for everybody, and if businesses are doing things by the book, they will see the benefits.

A clause in SQ 820 would give current Oklahoman business owners two years to apply for new licenses from the OMMA to serve recreational customers.

As the results of the March 7 poll trickle in, a wide variety of companies, including Advanced Container Technologies Inc. (OTC: ACTX), will be watching to see whether yet another state has decided to open a regulated recreational marijuana market.

NOTE TO INVESTORS: The latest news and updates relating to Advanced Container Technologies Inc. (OTC: ACTX) are available in the company’s newsroom at https://cnw.fm/ACTX

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

420 with CNW — Data Shows Increased Enforcement Against Illicit Marijuana Operations in California

Despite dozens of states legalizing cannabis use for either medical or recreational purposes, America’s illicit cannabis market is still going strong. Legal operators have struggled to compete with illicit sellers amid strict regulations and relatively high cannabis taxes that have made legal marijuana much more expensive than its illicit counterpart.

By the end of 2021, illicit sales of cannabis had reached close to $8 billion annually, doubling the volume of sales from legal operators and forcing many of them to close shop.

However, in California regulators are actively taking steps to reduce the illicit market’s stranglehold on the state’s cannabis industry.

Newly released data shows that the Department of Cannabis Control (DCC) has stepped up its efforts to curtail the state’s illicit market in the past two years. This campaign has seen a significant increase in court-issued warrants for illicit markets, eradication of illegal cannabis firms, seizures of firearms and arrests.

Statistics from the DCC show that the amount of search warrant operations increased by a whopping 150% from 62 in 2021 to 155 last year. There was also a 246% jump in illegal cannabis seizures from 144,254 pounds in 2022 to 31,726 pounds in 2022. Additionally, the number of arrests tripled to 56 while the total amount of illicit cannabis seizures in 2022 reached $243 million, an increase of 211% from around $78 million worth of illegal cannabis seizures in 2021.

In conjunction with other California agencies, the DCC managed to seize close to 439,800 pounds of illegal substances, worth almost $737 million in retail value. The agency destroyed 960,212 plants and confiscated 139 firearms from illicit cannabis operations. However, the hard cash confiscated in 2022 dropped by 77% from $7.7 million in 2021 to $1.8 million in 2022.

All of these efforts are meant to curtail the largest illicit cannabis industry in not just America but the entire world. This illicit market has made it extremely difficult for approved sellers to stay afloat, robbed the state of hundreds of millions of dollars in revenue and contributed to environmental pollution.

With experts positing that California’s illicit market is double the size of the legal market, law enforcement agencies have had a challenging time reining in the runaway industry. As such, federal, county, and local agencies have been forced to partner up to deal with the state’s massive illicit cannabis market.

Lighter punishments for illicit cannabis possession have also made it harder for law enforcement to deal with illicit sellers, with  Sgt. Rich Debevec of the San Bernardino County Sheriff’s Marijuana Enforcement Team saying in a recent interview that most offenders are given tickets.

No such light punishments exist for entities operating within the purview of the FDA, which is why for-profit companies such as India Globalization Capital Inc. (NYSE American: IGC) are taking their product pipeline through a meticulous preclinical and clinical development process so that once the THC-based formulations are approved, no questions will arise about their efficacy or safety profile.

NOTE TO INVESTORS: The latest news and updates relating to India Globalization Capital Inc. (NYSE American: IGC) are available in the company’s newsroom at https://cnw.fm/IGC

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

CannabisNewsBreaks – India Globalization Capital Inc. (NYSE American: IGC) Bringing Hope for Alzheimer’s Treatment

India Globalization Capital (NYSE American: IGC) is developing a cannabis-based investigational drug that is being tested for the first time ever on humans in an FDA-approved study. This is groundbreaking work that established its commitment as a pioneer in the treatment of Alzheimer’s disease, given there are no currently FDA-approved drugs to treat Alzheimer’s patients. “The company is developing its proprietary treatment, IGC-AD1, hoping to provide relief to the 55 million people worldwide struggling with agitation in dementia that results from Alzheimer’s. IGC is focused on revolutionizing the treatment of Alzheimer’s with its game-changing drug candidate. In phase 1 studies, IGC-AD1 shows potential to safely reduce the debilitating symptoms that impact millions of Alzheimer’s patients and their caregivers. Featuring a low dose of THC, the treatment is the first natural cannabis-based investigational drug being tested in human FDA trials to treat Alzheimer’s patients; it provides medical benefits without psychoactive effects. ‘As millions of Alzheimer’s patients continue to suffer from agitation, anxiety and depression, phase 2 clinical trials bring hope for a treatment,’ the company reports.”

To view the full article, visit https://cnw.fm/AgjeC

About India Globalization Capital Inc.

IGC develops advanced cannabinoid-based formulations for treating diseases and conditions including but not limited to Alzheimer’s, period cramps (dysmenorrhea), premenstrual syndrome (“PMS”) and chronic pain. The company has two investigational drug assets targeting Alzheimer’s disease, IGC-AD1 and TGR-63, that have demonstrated in Alzheimer’s cell lines the potential to be effective in suppressing or ameliorating key hallmarks of the disease such as plaques and tangles. IGC-AD1 is a low-dose tetrahydrocannabinol (“THC”) based formulation that is currently in a 146-person, phase 2B safety and efficacy clinical trial for agitation in dementia due to Alzheimer’s (clinicaltrials.gov, NCT05543681). The company also markets two wellness brands, Holief and Sunday Seltzer. Holief targets women experiencing premenstrual syndrome and menstrual cramps and Sunday Seltzer is a lifestyle hemp-infused energy beverage brand. The company is headquartered in Maryland, USA, and has historically operated an infrastructure segment based in India.

NOTE TO INVESTORS: The latest news and updates relating to IGC are available in the company’s newsroom at https://cnw.fm/IGC

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

To receive SMS text alerts from CannabisNewsWire, text “Cannabis” to 844-397-5787 (U.S. Mobile Phones Only)

For more information please visit https://www.cannabisnewswire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.cannabisnewswire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is part of the InvestorBrandNetwork.

CannabisNewsBreaks – Grapefruit USA Inc. (GPFT) Issues Update on DLC Acquisition, Long-Term Strategic Plans

Grapefruit USA (OTCQB: GPFT), an innovative California-based cannabiotech company, today provided an update to its recent announcement regarding the proposed acquisition of Diagnostic Lab Corporation Inc. of Englewood Cliffs, New Jersey (“DLC”), a diversified food and agriculture safety company, as well as the proposed recapitalization of the company. “We are providing this update to inform our many loyal shareholders that the company is making significant progress with respect to the DLC acquisition and securing additional capital, despite the challenging current macro-economic environment and its influence on the capital markets. Grapefruit’s management, staff and outside professionals continue to work together very efficiently to ensure a successful acquisition of DLC,” said Bradley J. Yourist, Grapefruit’s CEO and co-founder. “Grapefruit is laying the groundwork to implement the company’s long-term strategic plans to acquire several retail stores in the eastern part of the United States as the next event in the company’s evolution to a wellness-driven, medical science-based, canna-focused biotech company.”

To view the full press release, visit https://cnw.fm/WhloA

About Grapefruit USA Inc.

Grapefruit’s corporate headquarters is in Westwood, Los Angeles, California. Grapefruit holds California permits and licenses to both manufacture and distribute cannabis products in the Golden State. Grapefruit’s extraction laboratory and manufacturing and distribution facilities are located in the industry-recognized Coachillin’ Industrial Cultivation and Ancillary Canna-Business Park in Desert Hot Springs, located on the extension of North Canyon Road, approximately 14 miles north of downtown Palm Springs. For more information about the company and its operations, visit www.GrapefruitBlvd.com.About CannabisNewsWireCannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.To receive SMS text alerts from CannabisNewsWire, text “Cannabis” to 844-397-5787 (U.S. Mobile Phones Only)For more information please visit https://www.cannabisnewswire.comPlease see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/DisclaimerDo you have questions or are you interested in working with CNW? Ask our EditorCannabisNewsWire (CNW)Denver, Coloradowww.cannabisnewswire.com303.498.7722 OfficeEditor@CannabisNewsWire.comCannabisNewsWire is part of the InvestorBrandNetwork.

Lexaria Bioscience Corp. (NASDAQ: LEXX) Releases Additional Findings From Human Clinical Study, Demonstrating DehydraTECH(TM)-CBD Effects on Hypertension

  • The global antihypertensive drugs market was valued at around $20.5 billion in 2021 and is expected to reach $39.5 billion by 2030, growing at a CAGR of 2.95%
  • Lexaria’s patented DehydraTECH(TM) technology is designed to formulate and deliver lipophilic drugs and active pharmaceutical ingredients (“APIs”), increasing effectiveness and improving how drugs are delivered into the bloodstream
  • DehydraTECH is suitable for use with a wide range of product formats, including pharmaceuticals, nutraceuticals, and over-the-counter capsules, pills, tablets, or oral suspensions
  • Lexaria is continuing to evaluate the results of its HYPER-H21-4 human clinical study and will report additional findings as they become available

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, recently announced additional findings from its human clinical study HYPER-H21-4, demonstrating a potentially novel mechanism of action of its patented DehydraTECH(TM)-processed cannabidiol (“CBD”) capsule formulation in reducing blood pressure. The FDA lays out clear guidelines for sponsors seeking to develop new anti-hypertension drugs, specifically defining the need for medications that offer complimentary modes of action. Lexaria believes that its latest results, detailed in the peer-reviewed and published in the journal “Biomedicine and Pharmacotherapy,” may support DehydraTECH-CBD qualification within the FDA guidelines (https://cnw.fm/vSYeP).

The global antihypertensive drugs market was valued at around $20.5 billion in 2021. The market is expected to grow at a CAGR of 2.95% between 2022 and 2030, resulting in a value of $39.5 billion, as a result of a worldwide increase in the number of hypertension cases. Hypertension is a common but serious medical condition, with more than 1.13 billion people suffering, according to the World Health Organization (“WHO”) (https://cnw.fm/YZ7ad).

Lexaria’s DehydraTECH is designed to formulate and deliver lipophilic (fat-soluble) drugs and active pharmaceutical ingredients (“APIs”). DehydraTECH increases the effectiveness and improves the way APIs enter the bloodstream. The benefits of consuming a DehydraTECH-enabled drug or product include:

  • Speed up in delivery time – with the effects felt by the consumer in minutes versus hours
  • Increased bioavailability – with more delivery of the drug into the bloodstream than traditional methods
  • Increased brain absorption – animal testing suggests significant improvement in the quality of the drug delivered across the blood-brain barrier
  • Improved drug potency – more of the ingested product is made available to the body, with lower dosages required to achieve desired effects
  • Reduction in drug administration costs – lower dosages mean lower overall drug costs

Animal studies of DehydraTECH have demonstrated the ability to elevate the quantity of the drug delivered across the blood-brain barrier by as much as 1,900 percent. Not only did those studies support additional patent applications, the results could be impactful to its hypertension program given that human blood pressure is in large part controlled by the central nervous system. The technology is also being evaluated for additional orally administered API’s, including  cannabinoids,  nicotine, and more. Lexaria currently possesses 28 granted patents, with many more pending worldwide.

Lexaria’s technology is best thought of as a foundation that providers of drugs and consumer supplements can utilize to improve the effectiveness of their existing or planned new offerings. DehydraTECH is suitable for use with a wide range of product formats, including pharmaceuticals, nutraceuticals, and over-the-counter capsules, pills, tablets, or oral suspensions.

Lexaria continues to study endpoint analyses as described in the complete study protocol for HYPER-H21-4, and any relevant material findings will be reported as they become available.

For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.cannabisnewswire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.cannabisnewswire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is part of the InvestorBrandNetwork.

420 with CNW — DOJ Launches Application for Federal Cannabis Pardon Certificates

Last week the Justice Department (DOJ) released an application form for those who were eligible for President Joseph Biden’s mass cannabis pardon to complete to prove that they received clemency. Biden issued an executive order in October pardoning those convicted of marijuana possession offenses in violation of federal law.

Although the pardon was automatic, activists have pushed government representatives to create a form that can be used to request certificates proving coverage. This might be helpful for individuals whose previous convictions are, for instance, keeping them from finding employment or housing.

Elizabeth Oyer, the pardon attorney, had stated in December that the online applications would be available soon, but regrettably, nothing of the sort happened, and as the months went by, activists’ impatience grew.

Anyone who received a pardon on Oct. 6, 2022, is qualified to receive a certificate of pardon. A person must have been accused of or found guilty of simple possession of cannabis in a federal court to qualify for a certificate. The applicant must have been in the country legally when the offense was committed. In a similar vein, a person must have been a citizen or a legally recognized permanent resident of the United States on Oct. 6, 2022.

The form can be completed online or printed out and mailed in. It entails basic questions regarding a person’s federal marijuana offense qualification as well as location information. Additionally, applicants must present documentation of any prior charges or convictions.

According to a Federal Register draft notice released by the Pardon Attorney’s office, the data could also be leveraged to perform statistical analyses of the characteristics of pardon applicants and recipients. The application is simple and takes about 10 to 30 minutes to complete. It includes instructions to follow, one page to fill out, and a page for appending the applicant’s signature.

The Congressional Marijuana Caucus’ cochair, Rep. Earl Blumenauer (D-OR), praised the application launch, stating that it was another positive move in President Biden’s administration in accepting the new marijuana realities.

The scope of Biden’s pardon declaration was fairly constrained; it didn’t release any person who is at the moment behind bars and did not include individuals who were found guilty of selling marijuana.

The office of the Pardon Attorney anticipates receiving close to 20,000 applications for certificates once the form receives final approval from the White House Office of Budget and Management. The draft will be open for public comment for 30 days.

The launch of this pardon certificate application is a welcome development that advocates and industry actors such as Advanced Container Technologies Inc. (OTC: ACTX) are likely to applaud, given its potential to fix some of the lasting adverse effects of prohibition upon those with minor cannabis convictions on their records.

NOTE TO INVESTORS: The latest news and updates relating to Advanced Container Technologies Inc. (OTC: ACTX) are available in the company’s newsroom at https://cnw.fm/ACTX

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

420 with CNW — Two Cannabis Legalization Measures in Wyoming Fail to Make 2024 Ballot

Cannabis reform activists in Wyoming ran into a wall after two measures meant to legalize medical marijuana and decriminalize cannabis possession failed to make it to the 2024 ballot. Wyoming NORML, one of the primary sponsors of the cannabis legalization measures, said last week that activists collected enough signatures to qualify for the ballot. However, the organizers did not gather enough petitions in two-thirds of Wyoming counties to meet the state’s required minimum percentage.

The activists said that despite failing to get the measures on next year’s ballot, they will continue working with lawmakers in the upcoming legislative session to bring the legislation to the floor and before voters in upcoming election cycles. Wyoming NORML executive director Bennett Sondeno noted that the road to cannabis reform in Wyoming will be difficult. He stated that although cannabis reformists in the state have plenty of backers in both the House and Senate, they have been prevented from acting with compassion and justice by “powerful string pullers and funders.”

Still, Sondeno continued, it was important for cannabis reform activists to keep the push for a ballot measure alive, stating that the campaign is hoping to work with state legislators to give Wyoming residents a chance to vote on cannabis legalization. He also said that the campaign is currently raising funds for professional petitioners to ensure that voters have the chance to decide on cannabis reform even if lawmakers remain resistant to the notion.

The campaign managed to collect 48,687 raw signatures for the medical cannabis measure and 47,426 signatures for the measure to decriminalize the possession of small amounts of cannabis. According to campaign organizers, these numbers were raw signature counts and had not been validated and authenticated by the state.

Even though the organizers met the state threshold of 15% of votes cast in the previous general election (41,776), they did not meet the 15% threshold from two-thirds of Wyoming’s counties in two counties. Previous efforts to get a measure onto the 2022 ballot were held back by poor weather conditions and the coronavirus pandemic that ultimately hampered signature collection efforts.

Sondeno says that the campaign is confident that future measures will qualify for the ballot, especially as the signature threshold will be lower after Wyoming’s latest midterm election cycle. He noted that the campaign will pool all of its efforts onto a measure to decriminalize possession and one to launch a medical cannabis program.

The medical marijuana measure would allow patients to purchase and possess up to 20 grams of “medical cannabis-derived products” and four ounces of cannabis flower.

On the other hand, the decriminalization measure would impose minor fines on individuals caught possessing up to four ounces of cannabis without any jail time.

For patients in Wyoming who had hoped to access medical marijuana soon, not all is lost. Many companies, such as India Globalization Capital Inc. (NYSE American: IGC), are focusing on making pharmaceutical-grade medicines from different cannabinoids such as THC, and once those medicines are approved by the FDA, they will be readily available across the country by prescription.

NOTE TO INVESTORS: The latest news and updates relating to India Globalization Capital Inc. (NYSE American: IGC) are available in the company’s newsroom at https://cnw.fm/IGC

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.